Simmons Bank held its stake in Edwards Lifesciences Corporation (NYSE:EW) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,010 shares of the medical research company’s stock at the end of the first quarter. Simmons Bank’s holdings in Edwards Lifesciences Corporation were worth $377,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of EW. GSA Capital Partners LLP increased its stake in Edwards Lifesciences Corporation by 43.5% in the fourth quarter. GSA Capital Partners LLP now owns 3,354 shares of the medical research company’s stock worth $314,000 after buying an additional 1,016 shares during the last quarter. South Texas Money Management Ltd. increased its stake in Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock worth $32,437,000 after buying an additional 211,119 shares during the last quarter. Advisor Partners LLC increased its stake in Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock worth $460,000 after buying an additional 341 shares during the last quarter. American Century Companies Inc. increased its stake in Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock worth $192,550,000 after buying an additional 137,934 shares during the last quarter. Finally, Torch Wealth Management LLC bought a new stake in Edwards Lifesciences Corporation during the first quarter worth $1,635,000. Institutional investors own 84.41% of the company’s stock.
Edwards Lifesciences Corporation (EW) traded up 0.03% during mid-day trading on Friday, hitting $114.99. 1,548,830 shares of the stock traded hands. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a 50-day moving average of $113.46 and a 200 day moving average of $98.41. The firm has a market capitalization of $24.13 billion, a P/E ratio of 38.23 and a beta of 0.75.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.12. Edwards Lifesciences Corporation had a return on equity of 25.80% and a net margin of 20.85%. The company had revenue of $883.50 million during the quarter, compared to analyst estimates of $776.51 million. During the same quarter last year, the firm posted $0.71 earnings per share. The firm’s revenue was up 26.7% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.53 EPS for the current year.
EW has been the topic of a number of research analyst reports. Northland Securities set a $105.00 price target on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a research note on Monday, March 20th. Vetr upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $116.04 price target on the stock in a research note on Thursday, May 4th. Evercore ISI upgraded shares of Edwards Lifesciences Corporation from an “in-line” rating to an “outperform” rating and raised their price target for the company from $98.50 to $110.00 in a research note on Monday, March 27th. Jefferies Group LLC restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Finally, Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $120.38.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Bernard J. Zovighian sold 18,050 shares of the firm’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $109.21, for a total value of $1,971,240.50. The disclosure for this sale can be found here. Insiders sold 284,221 shares of company stock valued at $31,023,158 in the last ninety days. 2.13% of the stock is currently owned by insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230501/simmons-bank-maintains-position-in-edwards-lifesciences-corporation-ew.html
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.